preloader
Wednesday, February 21, 2024
Follow us on :

These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q3 Results

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported upbeat earnings for its third quarter, while sales missed estimates.

Vertex Pharmaceuticals posted adjusted earnings of $4.08 per share, beating market estimates of $3.98 per share. The company’s quarterly sales came in at $2.48 billion versus expectations of $2.50 billion.

Vertex said it now sees FY23 sales of around $9.85 billion from its CF treatments.

Vertex shares fell 0.6% to trade at $383.51 on Tuesday.

These analysts made changes to their price targets on Vertex Pharmaceuticals following earnings announcement.

  • HC ...

Full story available on Benzinga.com


Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.


Disclaimer Press Release Banner